InvestorsObserver
×
News Home

Is Alcon AG (ALC) a Stock to Watch After Gaining 1.66% This Week?

Wednesday, September 08, 2021 12:36 PM | InvestorsObserver Analysts

Mentioned in this article

Is Alcon AG (ALC) a Stock to Watch After Gaining 1.66% This Week?

Alcon AG (ALC) stock has gained 1.66% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bullish
Alcon AG has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ALC!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ALC Stock Today?

Alcon AG (ALC) stock is trading at $83.84 as of 12:33 PM on Wednesday, Sep 8, a loss of -$1.10, or -1.3% from the previous closing price of $84.94. The stock has traded between $83.34 and $83.91 so far today. Volume today is below average. So far 222,438 shares have traded compared to average volume of 940,128 shares. To screen for more stocks like Alcon AG click here.

More About Alcon AG

Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan. Click Here to get the full Stock Report for Alcon AG stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App